Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

A.P. Pharma to Hold Third Quarter 2001 Conference Call Nov. 6, 2001.


Business Editors

REDWOOD CITY Redwood City, city (1990 pop. 66,072), seat of San Mateo co., W Calif., on San Francisco Bay; inc. 1868. Manufactures include commmunications, electrical, electronic, and medical equipment. , Calif.--(BUSINESS WIRE)--Oct. 31, 2001

A.P. Pharma Inc. (Nasdaq:APPA), a specialty pharmaceutical company, will release 2001 third quarter financial results prior to market open on Tuesday, Nov. 6, 2001.

Paul Goddard This article is about an English footballer. For the Australian actor of the same name, see Paul Goddard (actor).
Paul Goddard (b. 12 October, 1959 in Harlington, Middlesex) is a former professional footballer and football manager.
, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tuesday, Nov. 6, 2001 to discuss the results and to answer questions.

To participate in the live call via telephone, call 800/618-9649. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 800/633-8284, and entering reservation number 19950333.

Individuals interested in listening to the conference call via the Internet may do so by visiting www.appharma.com. A replay will be available on the company's Web site for 14 days.

About A.P. Pharma

A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The company's primary focus is the development and commercialization of its bioerodible injectable in·ject·a·ble
adj.
Capable of being injected. Used of a drug.

n.
A drug or medicine that can be injected.
 and implantable systems under the trade name Biochronomer(TM).

Initial targeted areas of application for the company's drug delivery technology include pain management, inflammation, anti-adhesion and protein delivery applications. The company's product development programs are funded by royalties from topical topical /top·i·cal/ (top´i-k'l) pertaining to a particular area, as a topical antiinfective applied to a certain area of the skin and affecting only the area to which it is applied.

top·i·cal
adj.
 products currently marketed by pharmaceutical partners and proceeds from the divestiture The breakup of AT&T. By federal court order, AT&T divested itself on January 1, 1984 of its 23 operating companies, which became known as the Regional Bell Operating Companies (RBOCs).  of its cosmeceutical cos·me·ceu·ti·cal
n.
A cosmetic that has or is purported to have medicinal properties.
 product lines.

For further information visit the company's Web site at www.appharma.com.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Oct 31, 2001
Words:261
Previous Article:CIRB: California Construction Volume Drops 25.8%.
Next Article:Tru Dynamics International Inc. Announces Letter of Intent to Sell Tru Wellness Korea Ltd.
Topics:



Related Articles
Second New Drug Application Filed for Retin-A Micro; Potential to Significantly Increase A.P. Pharma's Royalties.
A.P. Pharma Reports Third Quarter 2001 Results; Carac Achieves 26% Topical Market Share in Second Quarter after Launch.
Organogenesis Schedules Conference Call to Discuss Third Quarter of 2001 Results.
A.P. Pharma Reports Initiation of Clinical Program for APF 112; First Clinical Study Fully Enrolled.
A.P. Pharma To Hold Fourth Quarter Conference Call March 5, 2002.
A.P. Pharma Reports Fourth Quarter and Year-End 2001 Results; Substantial Progress for the Biochronomer Drug Delivery System in 2001.
A.P. Pharma to Hold First Quarter Conference Call May 7, 2002.
A.P. Pharma Reports First Quarter Results; Clinical Program for APF112 Initiated in 2002; Royalty Income Up 39% Over First Quarter 2001.
Second Formulation of RETIN-A MICRO Approved for U.S. Market; Launch Anticipated in June 2002; Potential to Significantly Increase A.P. Pharma's...
A.P. Pharma Reports Third Quarter Financial Results; Third Quarter Royalty Income Increases 30%.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles